Skip to main content

Exact Sciences Nets $64.7M from Stock Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences has completed its public offering of common stock, raising net proceeds of roughly $64.7 million.

The Madison, Wis.-based molecular diagnostics firm sold 11.5 million shares, which included an over-allotment option of 1.5 million shares, at $6 per share. The firm launched the offering last week.

Exact Sciences said that it will use the proceeds from the offering to support clinical trials of its stool-based DNA colorectal cancer screening test. In addition, the funds may be used "strategic initiatives," it said.

Two weeks ago, the firm presented results from a validation study for the test.

In early Wednesday trade on the Nasdaq, shares of Exact Sciences were down 2 percent at $6.13.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.